Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

96
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
96
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

2.7K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.7K
iPS Cell Differentiation01:22

iPS Cell Differentiation

2.7K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.7K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

312
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
312
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.5K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

134
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
134

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of Patients.

Acta dermato-venereologica·2026
Same author

A case series of immune checkpoint inhibitor-induced bullous pemphigoid successfully treated with dupilumab and evidence for the BP180 midportion epitope as a preferential autoantigenic target.

Frontiers in medicine·2026
Same author

Dermatological manifestations in MORC2-related neuropathy and cerebellar atrophy.

Italian journal of dermatology and venereology·2026
Same author

Tufted hair folliculitis as an unusual cutaneous manifestation of systemic Langerhans cell histiocytosis.

Italian journal of dermatology and venereology·2026
Same author

Optimizing Local Treatment in Pemphigus and Pemphigoid: Current Evidence and Unmet Needs.

International journal of dermatology·2026
Same author

Flow cytometry helps differentiate between mucous membrane pemphigoid and erosive oral lichen planus.

Scientific reports·2026

Related Experiment Video

Updated: Jul 12, 2025

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.5K

[Pemphigus: current and future treatment strategies].

Jacqueline Kussini1, Tabea Kaisers2, Antonio Manuel Sequeira Santos1

  • 1Klinik für Dermatologie und Allergologie, Philipps-Universität Marburg, Baldingerstr., 35043, Marburg, Deutschland.

Dermatologie (Heidelberg, Germany)
|October 30, 2023
PubMed
Summary

Pemphigus is an autoimmune disease causing blisters on skin and mucosae. Treatment involves systemic therapy, including corticosteroids, immunosuppressants, or rituximab for severe cases.

Keywords:
AutoantibodiesAutoimmune skin diseasesBlistering skin diseasesCorticosteroidsImmunosuppressive drugs

More Related Videos

Isolation, Culture, and Genetic Engineering of Mammalian Primary Pigment Epithelial Cells for Non-Viral Gene Therapy
09:46

Isolation, Culture, and Genetic Engineering of Mammalian Primary Pigment Epithelial Cells for Non-Viral Gene Therapy

Published on: February 26, 2021

3.2K
Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
07:04

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

2.1K

Related Experiment Videos

Last Updated: Jul 12, 2025

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.5K
Isolation, Culture, and Genetic Engineering of Mammalian Primary Pigment Epithelial Cells for Non-Viral Gene Therapy
09:46

Isolation, Culture, and Genetic Engineering of Mammalian Primary Pigment Epithelial Cells for Non-Viral Gene Therapy

Published on: February 26, 2021

3.2K
Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
07:04

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

2.1K

Area of Science:

  • Autoimmune diseases
  • Dermatology
  • Immunology

Context:

  • Pemphigus diseases are organ-specific autoimmune disorders.
  • Characterized by autoantibodies targeting intra-epidermal adhesion molecules.
  • Manifests as blisters and erosions on skin and mucosae.

Purpose:

  • To outline the recommended diagnosis and therapy for pemphigus diseases.
  • To detail current systemic treatment strategies.
  • To highlight the role of novel therapies like rituximab.

Summary:

  • Systemic therapy is recommended for pemphigus, as per AWMF S2k guidelines.
  • Initial treatment often involves high-dose oral corticosteroids combined with immunosuppressants (azathioprine or mycophenolate mofetil).
  • Rituximab, a CD20-targeting monoclonal antibody, is approved for pemphigus vulgaris and moderate to severe pemphigus foliaceus.

Impact:

  • Provides a concise overview of pemphigus management.
  • Informs clinicians about established and emerging treatment options.
  • Supports evidence-based practice in autoimmune blistering diseases.